3B Blackbio DX Ltd Q1 FY27 results (latest), Apr–Jun 2026 →See revenue, profit and what management said. You are viewing Q2 FY25.
3B

3B Blackbio DX Ltd

Q2 FY25Healthcare Services

3B Blackbio DX Q2 FY25 earnings call: Revenue & Margins

Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹29Cr
+52.6% YoY
+52.6% QoQ
Net profit
₹15Cr
+87.5% YoY
+36.4% QoQ
Margin
55%
+14 pp YoY
−1 pp QoQ

3B Blackbio DX Ltd Q2 FY25 key numbers

Revenue
Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. +48.5% YoY).

As stated in 3B Blackbio DX Ltd's Q2 FY25 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on 3B Blackbio DX Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹1,406
Market cap₹1.1K Cr
P/E20.4

The short version

Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. EBITDA for Q2 FY 2024-25: ₹1,929.17 lakh, up from ₹1,059.54 lakh in Q2 FY 2023-24.

From 3B Blackbio DX Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. +48.5% YoY).
  • Diagnostic division (3B BlackBio + TRUPCR Europe) Q2 revenue: ₹2,457.55 lakh vs ₹1,465.63 lakh in Q2 FY 2023-24 (approx. +67.6% YoY).
  • Export sales (non-COVID) in Q2 FY 2024-25: ₹366.50 lakh vs ₹170.17 lakh in Q2 FY 2023-24 (approx. +115% YoY).
  • TRUPCR Europe Ltd. (Manchester site) Q2 sales grew by 51% YoY to ₹404,900 GBP.
  • Molecular diagnostic sales for standalone 3B: ₹2,194.18 lakh in Q2 FY 2024-25 vs ₹1,410.19 lakh in Q2 FY 2023-24 (approx. +55.6% YoY).
  • Revenue spike from seasonal Flu, Dengue & Chikungunya in Q2 2024-25 contributed extra growth (~28%), expected not to continue in Q3/Q4.

2 more points from 3B Blackbio DX Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what 3B Blackbio DX Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 40).
  • Looking for inorganic growth via acquisition since FY22; will pursue only if it meets internal IRR criteria; may consider share buyback if acquisition candidate not found (Page 40).
  • Deployment of some funds planned in joint venture created in Manchester, UK, depending on need (Page 40).

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what 3B Blackbio DX Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

It provides related insights as follows: - The company has signed over 15 long-term contracts under the Reagent-Rental Model, projecting 20%-25% business contribution this financial year and beyond (Page 39). - Export business (non-COVID sales) increased substantially in Q2 2024-25 versus Q2 2023-24 due to tender business materializing and business growth in the UK (Page 18). - Sales in India operate through three models with projected contributions, including tender sales at 5%-7%, Reagent Rental Model at 20%-25%, and other supplies making up 65%-70% (Page 20).

3B Blackbio DX Ltd — Quarterly revenue & net profit

Revenue Net profit
Sep 2024Q2 FY25
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26

3B Blackbio DX Ltd Q2 FY25 results — key figures

3B Blackbio DX Ltd Q2 FY25 reported results vs Q2 FY24, ₹ crore
₹ CrQ2 FY25Q2 FY24YoYQ1 FY25QoQ
Revenue2919+52.6%19+52.6%
Operating profit (EBITDA)168+100%11+45.5%
Operating margin55%41%+14 pp56%-1 pp
Profit before tax1910+90%14+35.7%
Net profit (PAT)158+87.5%11+36.4%
EPS (₹)17.0710.46+63.2%12.97+31.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹50 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

3B Blackbio DX Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were 3B Blackbio DX Ltd Q2 FY25 results?

Total consolidated sales/revenue for Q2 FY 2024-25: ₹3,258.35 lakh, up from ₹2,192.52 lakh in Q2 FY 2023-24 (approx. EBITDA for Q2 FY 2024-25: ₹1,929.17 lakh, up from ₹1,059.54 lakh in Q2 FY 2023-24.

What is 3B Blackbio DX Ltd share price analysis?

3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 20.4 with a market cap of ₹1,132 Cr. Investors should review the full earnings analysis for detailed insights.

Is 3B Blackbio DX Ltd planning capital expenditure?

The company is continuously investing in building additional manufacturing and R&D facilities/capacities to support existing business verticals (Page 40).

Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.